Hedgehog pathway inhibitors are therapeutic agents designed to block the aberrant activation of the Hedgehog signaling pathway. These inhibitors can target various components of the pathway, but most currently approved drugs focus on inhibiting the SMO protein, effectively halting downstream signaling and reducing cancer cell proliferation.